Answers are grounded in this paper and cite their sources.
Analysis shows increased insurance payments for cervical cancer in China, highlighting rising drug costs post-COVID-19.
The proportion of hospitalization expenses paid by insurance after COVID-19 is higher than that paid before COVID-19. Attention should be paid to the rising costs of drugs after the COVID-19 pandemic and reasonable control should be maintained for the diagnosis costs to reduce the total expenditure on cervical cancer patients after COVID-19.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: